TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04704609

Intervention type: OTHER
Intervention: Standard of Care Imaging
Description: We are collecting imaging that is standard of care for uveitis patients
Study: NCT02649283

Intervention type: DEVICE
Group type: OTHER
Intervention: OrbiSymm device
Description: Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Breast symmetrisation
Description: Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
Study: NCT00368966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7-valent Pneumococcal Conjugate Vaccine
Study: NCT03987152

Intervention type: DRUG
Group type: OTHER
Intervention: Sirolimus
Description: Daily intake of Sirolimus during Challenge and Rechallenge phase
Study: NCT00506909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU BID or 40 IU BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 20 IU BID or 40 IU BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 IU BID or 40 IU BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 20 IU BID or 40 IU BID
Study: NCT01495377

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion fluid, solution 9 mg/ml ( hydrogenic solution )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium
Description: 37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamometer (Jamar)
Description: portable hydraulic hand dynamometer to assess grip strength.
Study: NCT00748293

Intervention type: OTHER
Group type: OTHER
Intervention: Low-residue diet
Description: Commercialized (not yet marketed)low-residue diet
Study: NCT01111110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anti-static then static
Description: Albuterol using static chambers
Study: NCT01473225

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No calorie information
Description: No nutrition label will be provided in this condition.
Study: NCT02741232

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 1% with epinephrine 1/400000

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham block
Study: NCT01183416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3F8 monoclonal antibody and 13-cis-Retinoic Acid
Description: A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are \~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
Study: NCT04753333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electromyography biofeedback (EMG-BF)
Description: Participants in this group will receive electromyography biofeedback (EMG-BF) guided strength training with patellar taping
Study: NCT04340934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: REZUM system
Description: Rezūm is a system uses water steam energy to remove the particular part of the prostate that enlarges and causes symptoms due to BPH. Rezum involves a radiofrequency (RF) generator system and an endoscopic device that is introduced into the body via the urethra.
Study: NCT04753333

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sham electromyography biofeedback (EMG-BF)
Description: Participants in this group will receive Sham electromyography biofeedback (EMG-BF) guided strength training without patellar taping
Study: NCT00305565

Intervention type: DEVICE
Group type: OTHER
Intervention: VNS Therapy
Description: Received output current of 0.25 milliamps (mA)

Intervention type: DEVICE
Group type: OTHER
Intervention: VNS Therapy
Description: Received output current of 0.5-1.0 mA

Intervention type: DEVICE
Group type: OTHER
Intervention: VNS Therapy
Description: Received output current of 1.0-1.5 mA
Study: NCT03043963

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: Lengthen the duration of sleep time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Timing
Description: Regularize the timing of the sleep period.
Study: NCT00812500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
Study: NCT03600025

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Typbar-TCV vaccine
Description: vaccine will receive intramuscularly
Study: NCT00812500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
Study: NCT06545461

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruits and Vegetables (F+V)
Description: Participants will receive a prescribed amount of F+V designed to reduce their dietary acid intake by half. This typically amounts to 2-4 cups daily of F+V provided in weekly allotments. Amount provided will be that calculated for the participant multiplied times number of household members to assure participants eat the prescribed amount and do not share with household members.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate (NaHCO3)
Description: Participants will receive 0.3 mEq/kg bw/day NaHCO3 tablets to match the alkali provided by F+V given to F+V participants. This will be provided as 650 mg NaHCO3 tablets for an average of 4-5 tablets/day in two divided oral doses.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will receive standard medical care but no additional alkali (F+V nor NaHCO3).
Study: NCT03104010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin Injection
Description: Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somatropin Injection
Description: Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.
Study: NCT00000331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Drug
Study: NCT01397279

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: intravenous glucose tolerance test
Description: Administration of a 30% weight-adapted glucose bolus intravenously.
Study: NCT00812500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medium Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Protein
Description: Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
Study: NCT00537355

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate
Description: 6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Histamine
Description: 6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
Study: NCT01397279

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hyperinsulinemic euglycemic clamp
Description: Intravenous administration of 20% glucose and insulin over 3 hours

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: hyperinsulinemic euglycemic clamp
Description: Intravenous administration of 20% glucose and insulin over 3 hours
Study: NCT01154140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: treatment
Description: crizotinib 250mg orally continuous twice daily dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: treatment
Description: pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
Study: NCT00416195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2007

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04130152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib 125 mg once daily, day 1 to day 21, followed by 7 days off treatment in a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole: oral, 2.5 mg per day continuously. during the 28-day cycle.
Study: NCT03646071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX108
Description: RX108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RX108
Description: RX108
Study: NCT02080338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic bracket slot system
Description: Orthodontic treatment using different orthodontic bracket slot systems

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic bracket slot system
Description: Orthodontic treatment using different orthodontic bracket slot systems
Study: NCT01047111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagectomy
Description: Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
Study: NCT00254423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01394341

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Daily sc. injection, individual dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Daily sc. injection, individual dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Daily sc. injection, individual dosage

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide
Description: Daily sc. injection, individual dosage
Study: NCT02740335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octaplex
Description: OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beriplex P/N (Kcentra)
Description: Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (\~3 units/kg/min), up to a maximum rate of 8.4 mL/min (\~210 units/min).
Study: NCT02541409

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir
Description: Direct acting antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Interferon alfa-2a
Description: Antiviral agent used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
Study: NCT02150252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bu-Yang-Huan-Wu Tang
Description: control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
Study: NCT01544647

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual spa protocol
Description: In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active spa protocol
Description: 4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
Study: NCT01184612

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing; MI
Description: MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing; MI
Description: MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing; MI
Description: MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client.
Study: NCT03780972

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONL1204
Description: Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONL1204
Description: Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONL1204
Description: Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ONL1204
Description: Administration of ONL1204 - inhibitor of Fas(CD95) signaling by intravitreal injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Injection
Description: Injection of study drug into the eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Injection
Description: Injection of study drug into the eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Injection
Description: Injection of study drug into the eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal Injection
Description: Injection of study drug into the eye

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of ocular fluids
Description: vitreous and aqueous fluid collection by a tap and during vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of ocular fluids
Description: vitreous and aqueous fluid collection by a tap and during vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of ocular fluids
Description: vitreous and aqueous fluid collection by a tap and during vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of ocular fluids
Description: vitreous and aqueous fluid collection by a tap and during vitrectomy
Study: NCT00831402

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Oligobs Maxiode
Description: The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: controll group
Description: 50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
Study: NCT01043133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social marketing-based medical education intervention
Description: social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
Study: NCT02491970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone/Formoterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone/Salmeterol
Study: NCT00789685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Beta
Description: Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
Study: NCT01415726

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator
Description: For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 \~ 7 hrs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator
Description: For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 \~ 7 hrs.
Study: NCT03057717

Intervention type: OTHER
Group type: OTHER
Intervention: 2D ultrasound assessment
Description: 2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
Study: NCT00652717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily for 42 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.